Overview
Pfizer Inc. is a global pharmaceutical and biotechnology business based on 42nd Street in
Manhattan, New York. The company's name honors its co-founder, Charles Pfizer (1824-1906).
Pfizer is a pharmaceutical company that discovers and manufactures medications and vaccines for
immunology, cancer, cardiology, endocrinology, and neurology. The firm has many blockbuster
medications or products that produce yearly revenues of more than $1 billion USD.
The corporation is ranked 64th on the Fortune 500[3] and 49th on the Forbes Global 2000.
The Shareholding Pattern page of Pfizer Ltd. presents the Promoter's holding, FII's holding, DII's Holding, and
Share holding by general public etc.
Shareholding Pattern - Pfizer Ltd.
Holder's Name No of Shares % Share Holding
NoOfShares 45747732 100%
Promoters 0 0%
ForeignInstitutions 864905 1.89%
NBanksMutualFunds 3850950 8.42%
CentralGovt 63 0%
Others 2070400 4.53%
GeneralPublic 6874479 15.03%
FinancialInstitutions 2843893 6.22%
ForeignPromoter 29243042 63.92%
- ET
Management of Pfizer.
ALBERT BOURLA, DVM, PH.D.
Chairman and Chief Executive Officer.
As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose: Breakthroughs
that change patients’ lives, with a focus on driving the scientific and commercial innovation needed
to have a transformational impact on human health.
During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding a
number of senior global positions across a range of markets and disciplines.
BILL CARAPEZZI
Executive Vice President, Global Business Services and Transformation.
Bill Carapezzi is Executive Vice President, Global Business Services and Transformation, responsible
for global procurement, global financial shared services, human resources operations, real estate,
and the financial project management office, as well as for elements of commercial operations.
FRANK D'AMELIO
Chief Financial Officer and Executive Vice President, Global Supply.
Frank D’Amelio is the Chief Financial Officer and Executive Vice President, Global Supply, responsible
for corporate finance functions including audit, treasury, tax, insurance, operations planning and
analysis (OP&A), corporate controllership, business finance and analytics, and for Pfizer’s Global
Supply organization.
SWOT of Pfizer.
Strengths in the SWOT.
-Specialty Care, Primary Care, Emerging Markets, Oncology, Established Products, Nutrition,
Consumer Healthcare, Capsugel, and Animal Health are Pfizer's operational divisions.
-Pfizer owns a large number of patents. Prevnar 13 is Pfizers' best-selling vaccination worldwide.
-Pfizer is the largest pharmaceutical corporation in the United States. It is one of the Fortune 500
companies.
-One of the market leaders in the business. It made $51.7 billion in sales in 2019.
-Pfizer is one of the industry's oldest pharmaceutical businesses, and it has amassed a wealth of
market expertise.
-Pfizer has a lengthy history of producing and selling pharmaceuticals for the healthcare industry.
Weaknesses in the SWOT.
-Pfizer spends less on research and development than its competitors. It has the potential to weaken
Pfizer since R&D is the core of a pharmaceutical firm.
-Pfizer's primary problem is that it does not compromise on pricing.
Opportunities in the SWOT analysis
-Pfizer products are in great demand throughout the developed world. People are getting
increasingly concerned about their health. This may improve revenues in the healthcare sector.
-Pfizer can buy more firms in order to grow its company.
-Strategic alliances with other companies would open up new opportunities in emerging nations
where local pharmaceutical companies are the primary rivals.
-Profitability may be increased or increased further by diversifying one's portfolio.
-Pfizer has created a Coronavirus vaccine, which may be a major chance for the firm to produce
tremendous income and a strong brand image throughout the world.
Threats in the SWOT
-FDA Regulations might be significant.
-Exchange rate fluctuations might pose a significant risk.
-The global economic recession poses a significant risk.
-Government regulation might also pose a significant danger.
-Competition from other businesses might also pose a significant danger.
-Increasing gasoline prices may have an immediate or indirect impact on the vaccination delivery
network and pricing.
Competitive Analysis.
Merck & Co., Inc.
Merck & Co. (MRK), founded in the nineteenth century, is one of the world's major pharmaceutical
corporations today. Merck's primary emphasis areas are oncology and diabetes. Several of its top
ten revenue-generating medicines are classified as specialty medications since they treat rare
diseases.
Novartis AG is a pharmaceutical company.
Novartis AG (NVS), headquartered in Switzerland, is a global sales leader in the pharmaceutical
business. According to a FiercePharma article, Novartis is expected to become the world's largest
pharmaceutical by 2024. Prescription therapies for cancer, multiple sclerosis, and macular
degeneration are among its best-selling medicines.
Eli Lilly and Co.
Eli Lilly and Company (LLY) is a pharmaceutical corporation based in Indianapolis, Indiana. The firm is
named after Col. Eli Lilly, a scientist and Civil War veteran who started the company in 1876. Eli Lilly
and Company were the first to mass-produce the polio vaccine and insulin.
